The Securities and Exchange Commission has announced that it has resolved civil FCPA charges against the French drug company, Sanofi, and its Kazakh and Middle Eastern subsidiaries. The company will pay $25 million to settle allegations that it participated in bribery schemes to secure government tenders and increase prescriptions.
September 4, 2018
Pharmaceutical giant charged with bribery
Related by Topic
New Post
Millicom reveals that DOJ is investigating its Guatemalan subsidiary for possible FCPA violations
August 21, 2025
News Alert
New Post
FCPA charges filed against two businessmen accused of bribing Mexican energy officials
August 13, 2025
News Alert
SEC and DOJ close FCPA investigations into GE HealthCare
August 5, 2025
News Alert